Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.
Last trade$4.77
Day change-$0.185 (-3.74%)
Day range$4.69 – $4.92
Volume2,532,264
Market cap$2.65B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.65B
Price / earnings
212.88×
Price / book
6.78×
Price / sales
0.97×
EV / sales
0.97×
EV / EBITDA
208×
Profitability
Earnings per share
$0.02
Return on assets
1.65%
Return on equity
3.19%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.69×
Current ratio
1.55×
Quick ratio
1.55×
Cash ratio
0.77×
Cash flow
Price / cash flow
19.59×
Price / free cash flow
20.04×
Free cash flow
$132.28M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CLOV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$759.3M
$743.17M
$749.19M
$487.71M
$496.65M
$477.62M
$462.33M
$336.96M
Cost of revenue
$629.46M
$590.17M
$589.65M
$413.5M
$423.47M
$377.99M
$353.44M
$243.04M
Gross profit
$129.85M
$153M
$159.54M
$74.21M
$73.18M
$99.63M
$108.89M
$93.92M
Selling, general and administrative
$122.8M
$124.44M
$131.69M
$123.11M
$97.15M
$109.79M
$109.7M
$115.02M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$123.41M
$125M
$132.21M
$123.53M
$97.55M
$110.19M
$110.16M
$115.37M
Operating income
$6.44M
$28M
$27.33M
-$49.32M
-$24.38M
-$10.56M
-$1.27M
-$21.45M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$6.44M
$28M
$27.33M
-$49.32M
-$24.38M
-$10.58M
-$1.27M
-$21.48M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$6.44M
$28M
$27.33M
-$49.32M
-$24.38M
-$10.58M
-$1.27M
-$22.09M
Net income attributable to common shareholders
$6.44M
$28M
$27.33M
-$49.32M
-$24.38M
-$10.58M
-$1.27M
-$22.09M
EBITDA
$6.6M
$28.14M
$27.41M
-$49.4M
-$24.37M
-$10.67M
-$1.25M
-$21.49M
Basic earnings per share
$0.01
$0.05
$0.05
-$0.09
-$0.05
-$0.02
$0.00
-$0.04
Diluted earnings per share
$0.01
$0.05
$0.05
-$0.09
-$0.05
-$0.02
$0.00
-$0.04
Recent news
Company coverage with links to the original publishers.
The global insurtech market is expected to expand from USD 14 billion in 2026 to USD 638 billion by 2035, driven by adoption of AI, cloud computing, blockchain, machine learning, and IoT. Health insurtech leads market share, while North America dominates regionally with Asia expected to achieve higher growth rates. Strategic partnerships between traditional insurers and startups are fueling innovation and scalability.
Clover Health announced that CMS awarded its PPO Medicare Advantage plans a 5-Star rating and HMO plans a 4.5-Star rating for 2027. The company grew Medicare Advantage membership ~48% year-over-year to over 157,000 members. Clover maintained its #1 ranking among non-SNP PPO plans with a HEDIS score of 4.82 out of 5 Stars for the third consecutive year, demonstrating the effectiveness of its Counterpart Assistant platform in supporting physician decision-making.
Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D. to its Board of Directors, effective immediately. Senator Torricelli will serve on the Audit Committee while Dr. Miller will serve on the Clinical Committee. The appointments fill two board vacancies and bring the board to nine directors. Both appointees bring extensive experience in healthcare policy, Medicare Advantage, clinical practice, and business strategy.
Clover Health announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J. Miller, M.D., to its Board of Directors, effective immediately. Torricelli will serve on the Audit Committee while Dr. Miller will serve on the Clinical Committee. Both appointments bring complementary expertise in healthcare policy, Medicare Advantage, clinical practice, and business strategy to strengthen the company's governance and execution.
Clover Health CEO Andrew Toy sold 62,711 shares worth ~$292,860 on July 15, 2026, to cover tax withholding obligations from RSU vesting. The sale is non-discretionary and doesn't reflect a change in conviction. Toy retains a $44.68 million stake (~2% ownership). The stock has gained 57% over the past year but dropped 20% in July following a data breach disclosure. Q2 earnings are expected in early August.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.